Oct 29, 7:03 AM ET
Eli Lilly and Company reported third-quarter 2026 revenue of $24.4 billion, a 39 percent increase year-over-year, driven by strong global demand for Mounjaro and Zepbound. Net income reached $6.5 billion with reported earnings per share of $7.22. Driven by the strong quarterly performance, the company raised its full-year 2026 revenue guidance by $5.5 billion to a range of $91.0 to $92.0 billion.
- Worldwide revenue for Q3 2026 increased 39% to $24.4 billion compared with $17.6 billion in Q3 2025.
- Q3 2026 reported EPS was $7.22, up 16%, and non-GAAP EPS was $7.48, up 7%, both including $4.57 of acquired IPR&D charges.
- Full-year 2026 revenue guidance was raised to a range of $91.0 to $92.0 billion.
- Mounjaro Q3 2026 worldwide revenue grew 65% to $10.7 billion, and Zepbound U.S. revenue grew 48% to $5.3 billion.
Read the filing on SEC.gov ↗
Aug 5, 7:05 AM ET
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48% from a year earlier, with reported EPS of $7.94, up 26%. The company raised its full-year 2026 revenue guidance to $85.0 billion to $87.0 billion, but its non-GAAP EPS guidance range of $35.50 to $36.50 has a lower top end than the prior $35.50 to $37.00, reflecting $3.03 per share of acquired IPR&D charges from Q2 business development.
- Q2 2026 revenue rose 48% to $23.0 billion, driven by a 60% increase in volume, partially offset by a 13% decrease in realized prices.
- Reported EPS was $7.94 versus $6.29 a year earlier; non-GAAP EPS was $8.38 versus $6.31.
- Acquired IPR&D charges were $2.8 billion in Q2 2026, compared with $154 million in Q2 2025.
- Full-year 2026 revenue guidance rose to $85.0 billion to $87.0 billion from $82 billion to $85 billion; EPS guidance is now $35.50 to $36.50 from $35.50 to $37.00.
Read the filing on SEC.gov ↗
May 20, 4:30 PM ET
Eli Lilly completed an offering of eight series of notes on May 20, 2026, with net proceeds of approximately $8.94 billion before estimated offering expenses. Maturities run from 2028 to 2066, and the filing ties five series to the proposed Centessa Acquisition, requiring their redemption at 101% of principal if that deal is not completed or the company says it will not pursue it.
- Net proceeds of approximately $8.94 billion before estimated offering expenses, per the filing.
- Fixed rate notes carry coupons from 4.150% (2029 notes) to 5.700% (2066 notes).
- Floating rate notes due 2028 and 2029 pay Compounded SOFR plus 0.350% and 0.460%, respectively.
- If the Centessa Acquisition is not completed by five business days after the later of March 31, 2027 or any agreed later Outside Date, the 2029 floating, 2029, 2031, 2033 and 2036 notes must be redeemed at 101% of principal plus accrued int
Read the filing on SEC.gov ↗
Apr 30, 7:03 AM ET
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56% from a year earlier, and reported EPS of $8.26 versus $3.06. The company raised its full-year 2026 revenue guidance to $82.0 billion to $85.0 billion and its non-GAAP EPS guidance to $35.50 to $37.00, which matters to shareholders because it raises the company's own outlook for the year.
- Q1 2026 revenue was $19.8 billion, up 56% from $12.7 billion, driven by a 65% increase in volume, partly offset by a 13% decrease from lower realized prices.
- Reported EPS was $8.26 versus $3.06; non-GAAP EPS was $8.55 versus $3.34.
- Full-year 2026 revenue guidance rose to $82.0 billion to $85.0 billion from $80 billion to $83 billion; non-GAAP EPS guidance rose to $35.50 to $37.00 from $33.50 to $35.00.
- Reported gross margin was 81.9% of revenue, down 0.6 percentage points, primarily due to lower realized prices.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.